Cargando…
Topical rapamycin for facial angiofibromas in tuberous sclerosis complex
Facial angiofibromas are a common cutaneous manifestation of tuberous sclerosis complex. Although angiofibromas are usually asymptomatic, they can be highly disfiguring and can have a significant impact on patient quality of life. Treatment for facial angiofibromas is challenging. Recently, topical...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5496009/ https://www.ncbi.nlm.nih.gov/pubmed/28690858 http://dx.doi.org/10.1093/omcr/omx029 |
_version_ | 1783247884218531840 |
---|---|
author | Safa, Gilles |
author_facet | Safa, Gilles |
author_sort | Safa, Gilles |
collection | PubMed |
description | Facial angiofibromas are a common cutaneous manifestation of tuberous sclerosis complex. Although angiofibromas are usually asymptomatic, they can be highly disfiguring and can have a significant impact on patient quality of life. Treatment for facial angiofibromas is challenging. Recently, topical rapamycin has been proposed as an effective option to treat angiofibromas. Herein is reported a case of a 27-year-old woman whose facial angiofibromas were successfully treated with topical rapamycin without relevant side effects. |
format | Online Article Text |
id | pubmed-5496009 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-54960092017-07-07 Topical rapamycin for facial angiofibromas in tuberous sclerosis complex Safa, Gilles Oxf Med Case Reports Case Report Facial angiofibromas are a common cutaneous manifestation of tuberous sclerosis complex. Although angiofibromas are usually asymptomatic, they can be highly disfiguring and can have a significant impact on patient quality of life. Treatment for facial angiofibromas is challenging. Recently, topical rapamycin has been proposed as an effective option to treat angiofibromas. Herein is reported a case of a 27-year-old woman whose facial angiofibromas were successfully treated with topical rapamycin without relevant side effects. Oxford University Press 2017-07-04 /pmc/articles/PMC5496009/ /pubmed/28690858 http://dx.doi.org/10.1093/omcr/omx029 Text en © The Author 2017. Published by Oxford University Press. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Case Report Safa, Gilles Topical rapamycin for facial angiofibromas in tuberous sclerosis complex |
title | Topical rapamycin for facial angiofibromas in tuberous sclerosis complex |
title_full | Topical rapamycin for facial angiofibromas in tuberous sclerosis complex |
title_fullStr | Topical rapamycin for facial angiofibromas in tuberous sclerosis complex |
title_full_unstemmed | Topical rapamycin for facial angiofibromas in tuberous sclerosis complex |
title_short | Topical rapamycin for facial angiofibromas in tuberous sclerosis complex |
title_sort | topical rapamycin for facial angiofibromas in tuberous sclerosis complex |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5496009/ https://www.ncbi.nlm.nih.gov/pubmed/28690858 http://dx.doi.org/10.1093/omcr/omx029 |
work_keys_str_mv | AT safagilles topicalrapamycinforfacialangiofibromasintuberoussclerosiscomplex |